HIV-associated neurocognitive disorders (HAND): Optimal diagnosis, antiviral therapy, pharmacological treatment, management, and future scopes.

In the context of HIV infection, HIV-associated neurocognitive disorders (HAND) have become a serious concern. An extensive summary of the diagnosis, care, and mental health consequences related to HAND is given in this article. The diagnosis of HAND entails a multimodal approach that includes neuroimaging, cognition tests, and clinical examinations. Numerous screening instruments and standardized evaluations have been created to support the early identification and tracking of HAND. Appropriate actions and individualized treatment plans are made possible by prompt diagnosis. A multidisciplinary approach is used in the treatment of HAND, aiming to address various elements of cognitive impairment. The main stream of treatment is still antiretroviral medication (ART), which successfully lowers viral loads and stops further neurocognitive deterioration. Adjunctive treatments are essential for treating cognitive symptoms and improving overall quality of life. These therapies include cognitive rehabilitation, pharmaceutical interventions, and psychological support. Our knowledge of the pathophysiology of HAND has improved with the identification of the inflammatory milieu and persistent viral persistence in the central nervous system (CNS), which has also aided in the creation of biomarkers for CNS illness. Although biomarkers show inflammation, neuronal damage, and monocyte activity, their clinical use is still restricted. Although new techniques to treating HAND have been developed as a result of a better knowledge of pathogenic processes, the best course of action is still unknown.